Two epigenetic regulators interfere with healthy aging

- Posted by admin in English

It has long been assumed that lifespan and health are strongly correlated, but although there has been an overall increase in human life expectancy in recent decades, it is too often accompanied by deterioration of health.

A new study published on February 26 in Nature shows the influence of two epigenetic regulators on aging. Scientists led by Jie Yuan from the Chinese Academy of Sciences in Shanghai have studied the BAZ-2 and SET-6 proteins in Caenorhabditis elegans worms, which are orthologs of the human proteins BAZ2B and EHMT1.

Through genome-wide RNA-interference-based screening of genes that regulate behavioral deterioration in aging C. elegans, the researchers identified 59 genes as potential health modulators during aging. Essentially the proteins expressed by these genes, read and write epigenetic signals.

Among these modulators, they found that a neuronal epigenetic reader, BAZ-2, and a neuronal histone SET-6, accelerate the deterioration of the behavior of C. elegans by reducing the mitochondrial function, and repressing the expression of the encoded mitochondrial proteins. in the cell nucleus.

The researchers found that the levels of the two proteins increase with age in C. elegans and mice, which in turn attenuates the expression of genes involved in mitochondrial function.

BAZ-2 and SET-6 are complementary epigenetic mechanisms. SET-6 is an "epigenetic writer" and BAZ-2 is an "epigenetic reader" which recognizes modified histones and recruits transcriptional regulators.

Histones are proteins located in the nucleus of eukaryotic cells. They are the main protein components of chromosomes. They are closely associated with DNA and allow their compaction, but they also modify the expression of proteins by various epigenetic mechanisms known as the "histone code".

enter image description here Source Wikipedia.

How do BAZ-2 and SET-6 accelerate aging? The researchers found that the two proteins bind together to the promoter regions of more than 2,000 genes, and decrease their expression via methylation of histones. Among these target genes are many mitochondrial genes encoded nuclear. By suppressing the expression of these genes, BAZ-2 and SET-6 reduce oxygen consumption and ATP production, and decrease the critical stress responses that maintain mitochondrial proteostasis. The resulting metabolic slowdown discourages the worms from assimilating their food and they mate less.

This mechanism is conserved in the neurons of cultured mice and human cells. What about the orthologs of these epigenetic proteins in humans? A review of the databases shows that expression by human orthologs of the two proteins mentioned above, BAZ2B and EHMT1, increases with age and is positively correlated with the progression of Alzheimer's disease. Researchers have verified that ablation of BAZ-2 mouse ortholog Baz2b attenuates age-dependent body weight gain and prevents cognitive decline in aging mice.

enter image description here While wild-type mice grew fat with age, animals lacking both copies of the epigenetic reader Baz2b stayed trim, indicating improved mitochondrial function. [Yuan et al., Nature, 2020.]

However, it must be asked whether BAZ-2 and SET-6 would rather mediate age-related physiological adaptation, rather than the agents of aging itself. Indeed their action could reflect a mechanism of adaptation to a progressively more hostile biological environment.

Old Article 5

- Posted by system in English

Old Article 4

- Posted by system in English

Old Article 3

- Posted by system in English

Old Article 2

- Posted by system in English

Old Article 1

- Posted by system in English

Significance of the Topic:

The study of sensory processing in autism spectrum disorder (ASD) is crucial due to its impact on an individual's quality of life. Up to 95% of autistic individuals experience sensory processing differences, which can lead to difficulties in social interactions, communication, and daily functioning. Understanding the complex relationship between hyper- and hyporesponsivity to sensory stimuli in ASD can provide valuable insights into the neural mechanisms underlying this condition.

Importance:

The study's findings have significant implications for the diagnosis, management, and treatment of ASD. By acknowledging the co-occurrence of hyper- and hyporesponsivity, clinicians can develop more comprehensive and targeted interventions that address the individual's unique sensory processing needs. This can improve the quality of life for autistic individuals and their families.

Timeliness:

The study's focus on the complex relationship between sensory hyper- and hyporesponsivity in ASD is especially timely. Recent advances in neuroimaging and computational modeling have enabled researchers to better understand the neural mechanisms underlying sensory processing. This study contributes to the growing body of research in this area, providing new insights that can inform the development of effective treatments and interventions.

Relevance:

The study's findings have relevance beyond ASD, as they may also apply to a broader range of neurological, psychiatric, and developmental conditions characterized by sensory processing difficulties. The "Sensory Paradox" framework proposed by the study offers a new perspective on sensory processing, which can be applied to various conditions, including ADHD, anxiety disorders, and intellectual disabilities.

Analysis of the Text:

  1. Background: The study begins by establishing the significance of sensory processing in ASD, highlighting the prevalence and impact of sensory processing differences in autistic individuals.
  2. Methods: The researchers describe their methodology, which involves assessing sensory hyper- and hyporesponsivity in 3-4-year-old children with ASD and typically developing children.
  3. Findings: The study reports a positive correlation between sensory hyper- and hyporesponsivity within and across sensory modalities, which the researchers term the "Sensory Paradox."
  4. Interpretation: The study's authors interpret the findings in the context of previous literature, suggesting that the "Sensory Paradox" provides a new framework for understanding sensory processing in ASD and other neurodevelopmental disorders.
  5. Funding: The study acknowledges the funding agencies that supported the research, highlighting the importance of continued funding for autism research.
  6. Research in Context: The study provides an overview of the existing literature on sensory processing in ASD, highlighting the need for a more comprehensive understanding of this complex phenomenon.
  7. Added Value: The study emphasizes the novel finding of the positive correlation between sensory hyper- and hyporesponsivity, which offers a new perspective on sensory processing.
  8. Implications: The study's authors discuss the implications of their findings for the diagnosis, management, and treatment of ASD, as well as their potential relevance to other neurological, psychiatric, and developmental conditions.

Usefulness for Disease Management or Drug Discovery:

The study's findings have significant implications for the development of effective treatments and interventions for ASD. By understanding the complex relationship between sensory hyper- and hyporesponsivity, clinicians can develop more targeted and comprehensive approaches to addressing sensory processing difficulties. This can improve the quality of life for autistic individuals and their families.

Originality:

The study's finding of the positive correlation between sensory hyper- and hyporesponsivity is a novel contribution to the field. While previous studies have identified both hyper- and hyporesponsivity in ASD, the study's emphasis on the co-occurrence of these two phenomena offers a new perspective on sensory processing.

Comparison with the State of Art:

The study's findings are consistent with previous research on sensory processing in ASD, which has highlighted the complex and variable nature of sensory processing difficulties in this population. However, the study's emphasis on the positive correlation between sensory hyper- and hyporesponsivity offers a new framework for understanding sensory processing in ASD and other neurodevelopmental disorders.

Read the original article on medRxiv

Analysis of the Text: Significance, Importance, Timeliness, and Relevance

The text discusses the relationship between plasma glial fibrillary acidic protein (GFAP), a marker of astrocytic activation, and Alzheimer's disease (Alzheimer's disease) in cognitively unimpaired (CU) older adults. The significance of this topic lies in its potential to provide insights into the early detection and monitoring of Alzheimer's disease, a debilitating neurodegenerative disorder affecting millions worldwide.

Importance:

  1. Early detection and prevention: Identifying prognostic biomarkers like GFAP can facilitate early detection and intervention, potentially slowing or preventing cognitive decline.
  2. Personalized medicine: The observed sex-specific vulnerability highlights the importance of considering individual factors, such as sex, in Alzheimer's disease research and treatment.
  3. Development of targeted therapies: Understanding the relationship between GFAP and Alzheimer's disease can inform the development of novel therapeutic approaches targeting astrocytic activation.

Timeliness:

  1. Advancements in Alzheimer's disease research: The study contributes to the growing field of Alzheimer's disease research, which has seen significant progress in recent years.
  2. Emergence of biomarkers: The identification of plasma GFAP as a prognostic biomarker aligns with the increasing focus on developing reliable biomarkers for Alzheimer's disease.

Relevance:

  1. Clinical implications: The findings have implications for the clinical management of Alzheimer's disease, particularly in the early stages of the disease.
  2. Research applications: The study's results can inform future research on the mechanisms underlying Alzheimer's disease and the development of effective treatments.

Analysis of the Text: Relationship between Items

  1. Plasma GFAP: Elevated plasma GFAP is associated with lower cognitive performance, greater amyloid burden, and faster cognitive decline in CU older adults.
  2. Amyloid burden: Higher amyloid burden is linked to elevated GFAP, suggesting a relationship between astrocytic activation and amyloid accumulation in Alzheimer's disease.
  3. Cognitive decline: Plasma GFAP predicts faster cognitive decline, highlighting its potential as a prognostic biomarker for Alzheimer's disease.
  4. Sex-specific vulnerability: The study reveals stronger associations between GFAP and Alzheimer's disease-related outcomes in females, underscoring the importance of considering sex-specific factors in Alzheimer's disease research.

Usefulness for Disease Management and Drug Discovery:

The study provides valuable insights into the relationship between plasma GFAP and Alzheimer's disease, which can inform the development of novel therapeutic approaches targeting astrocytic activation. Elevated GFAP may serve as a prognostic biomarker for Alzheimer's disease, enabling early detection and intervention. The observed sex-specific vulnerability highlights the need to consider individual factors, such as sex, in Alzheimer's disease research and treatment.

Originality of the Text:

The study provides original information by:

  1. Identifying plasma GFAP as a prognostic biomarker: The study demonstrates the predictive value of plasma GFAP in CU older adults, offering a potential new tool for Alzheimer's disease research and diagnosis.
  2. Highlighting sex-specific vulnerability: The findings emphasize the importance of considering sex-specific factors in Alzheimer's disease research and treatment, which is a relatively unexplored area of study.
  3. Investigating longitudinal associations: The study's longitudinal design allows for a more comprehensive understanding of the relationships between plasma GFAP, cognitive decline, and Alzheimer's disease-related outcomes.

Read the original article on medRxiv

BackgroundEnvironmental lead exposure has long been implicated in neurodegenerative disease. In Australia, population lead burdens rose steeply during the 20th century due to widespread use of leaded petrol, followed by a sharp decline after its phase-out in 2002. Prior ecological studies (Laidlaw et al., 2015; Zahran et al., 2017) proposed that motor neurone disease (MND) mortality follows cumulative lead exposure with an approximate 20-year latency, reflecting delayed toxic release from skeletal stores.

ObjectivesThis study re-examines the temporal relationship between national petrol-lead emissions and MND mortality in Australia using updated official mortality data (1986-2022) and the Kristensen (1958-2002) emissions inventory.

MethodsAge-standardised MND mortality rates from the Australian Institute of Health and Welfare were correlated with cumulative petrol-lead emissions under varying time-lag scenarios (0-30 years). Ordinary least squares regression models were fitted to identify the lag yielding the strongest association. A projection of MND mortality to 2035 was then generated using the optimal lag model, assuming constant cumulative lead exposure post-2002.

ResultsThe best-fit model occurred at a 20-year lag (R2 = 0.72, p = 1.9 x 10-5), consistent with Laidlaws estimated latency. The model indicates that MND mortality rises approximately two decades after peak cumulative petrol-lead exposure and subsequently stabilises and declines as high-exposure cohorts age out. Projections to 2035 show a gradual downward trend in national MND mortality following the 2002 lead phase-out.

ConclusionsThese findings corroborate earlier hypotheses linking lead exposure to MND mortality and provide quantitative evidence of a {approx} 20-year temporal lag between population-level lead accumulation and neurodegenerative outcomes. The biological plausibility of this delay aligns with the long half-life of skeletal lead and its role in oxidative neuronal injury. Persistent lead contamination therefore remains a continuing public-health concern with potential implications for adult neurodegenerative disease prevention.

Read the original article on medRxiv

Analysis of the Text: Significance, Importance, Timeliness, and Relevance

The text discusses the development and clinical performance of a prototype immunoassay, Elecsys(R) Phospho-Tau (217P) Plasma, for detecting amyloid-beta (Aβ) burden in Alzheimer's disease (AD) patients using plasma tau phosphorylated at threonine 217 (pTau217) as a biomarker. This topic is significant because it explores a potential solution for early and accurate diagnosis of AD, a leading cause of dementia.

Importance

The development of disease-modifying anti-Aβ therapies has created a pressing need for reliable and minimally invasive diagnostic tools. Blood-based biomarkers like pTau217 offer a promising solution for detecting Aβ burden, which is critical for identifying potential AD patients who can benefit from these therapies. The importance of this research lies in its potential to improve early detection, diagnosis, and treatment of AD.

Timeliness

The text is relevant to current research efforts in AD. In recent years, there has been a surge in interest in Aβ-targeting therapies, and the development of reliable biomarkers for detecting Aβ burden is essential for their success. The study's focus on plasma pTau217 as a biomarker is timely, given the existing research on the role of tau proteins in AD pathology.

Relevance

The study's findings are relevant to the clinical practice of diagnosing and managing AD. The Elecsys(R) Phospho-Tau (217P) Plasma immunoassay has shown high accuracy in reflecting Aβ burden, suggesting its potential implementation in routine clinical practice to aid early detection of AD. This is particularly important for individuals presenting with cognitive complaints across diverse clinical settings.

Insights into the Usefulness of the Text for Disease Management and Drug Discovery

The text provides valuable insights into the potential usefulness of plasma pTau217 as a biomarker for detecting Aβ burden in AD patients. The study's findings suggest that this biomarker could be used to:

  1. Improve early detection and diagnosis of AD, enabling timely intervention with disease-modifying therapies.
  2. Enhance the accuracy of AD diagnosis, particularly in individuals with subjective cognitive impairment.
  3. Inform treatment decisions, such as the selection of patients for Aβ-targeting therapies.

Original Information Beyond the Obvious

The text provides original information beyond the obvious in several areas:

  1. The study's focus on plasma pTau217 as a biomarker for Aβ burden is a novel contribution to the field.
  2. The clinical performance of the prototype Elecsys(R) Phospho-Tau (217P) Plasma immunoassay in a large, unselected cohort is an important finding.
  3. The study's subgroup analyses, including the influence of kidney function on plasma pTau217 levels, offer valuable insights into the potential limitations and applications of this biomarker.

However, it is essential to note that the study's findings are based on a single biomarker and a specific immunoassay, and further research is needed to confirm these results and explore the broader implications of plasma pTau217 as a biomarker for AD.

Read the original article on medRxiv


Please, help us continue to provide valuable information: